Compare Crispr Therapeutics AG (CRSP) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nutanix Inc — how do they compare? Crispr Therapeutics AG trades at $51.49 (market cap $4.97B), while Nutanix Inc trades at $54.87 (market cap $14.99B). The key difference: Nutanix Inc is far larger — about 3× Crispr Therapeutics AG's market cap, and Nutanix Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | NTNX | |
|---|---|---|
Market Cap | $4.97B | $14.99B |
Sector | Health | Technology |
52-Week High | $76.78 | $81.12 |
52-Week Low | $44.34 | $34.41 |
Enterprise Value | $3.32B | $14.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Nutanix (NTNX) trades at $55.22, up 0.78% on the day, reflecting positive momentum. The stock exhibits a bullish technical trend with strong moving average support and is trading near key resistance at $56. Fundamentally, the company demonstrates robust revenue growth, with Q3 2026 results beating expectations, and maintains a high gross profit margin of 87.09%. Recent news highlights strategic partnerships and NVIDIA certification for its AI infrastructure solutions.
The outlook for NTNX is positive, driven by consistent earnings beats, strong analyst consensus (62.5% Buy ratings), and a $57.80 price target suggesting modest upside. Key risks include its high valuation multiples (P/E of 58.39) and execution challenges in a competitive cloud software market. Investor sentiment is buoyed by its positioning in hybrid multicloud and AI growth areas.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
